

# Evaluation of the Association of *IGF2BP2* Variants With Type 2 Diabetes in French Caucasians

Konsta Duesing,<sup>1</sup> Ghazaleh Fatemifar,<sup>1</sup> Guillaume Charpentier,<sup>2</sup> Michel Marre,<sup>3,4</sup> Jean Tichet,<sup>5</sup> Serge Hercberg,<sup>6</sup> Beverley Balkau,<sup>7,8</sup> Philippe Froguel,<sup>1,9</sup> and Fernando Gibson<sup>1</sup>

**OBJECTIVE**—We performed a comprehensive genetic association study of common variation spanning the *IGF2BP2* locus in order to replicate the association of the “confirmed” type 2 diabetes susceptibility variants rs4402960 and rs1470579 in the French Caucasian population and to further characterize the susceptibility variants at this novel locus.

**RESEARCH DESIGN AND METHODS**—We genotyped a total of 21 tagging single nucleotide polymorphisms spanning the *IGF2BP2* locus in our type 2 diabetes case-control cohort comprising 3,093 French Caucasian subjects.

**RESULTS**—*IGF2BP2* variants rs4402960 and rs1470579 were not associated with type 2 diabetes in the present study ( $P = 0.632$  and  $P = 0.896$ , respectively). Meta-analysis of genotype data from over 34,000 subjects demonstrated that our inability to replicate rs4402960/rs1470579 was consistent with the findings from several previous genome-wide association study (GWAS) datasets that were underpowered to detect this modest association signal (odds ratio [OR] 1.14). We obtained novel evidence that rs9826022, a borderline rare variant (5% minor allele frequency) in the 3′ downstream region, was associated with type 2 diabetes ( $P = 0.0002$ ; OR 1.53 [95% CI 1.22–1.91]). This result was corroborated by the meta-analysis of 10,542 genotypes from the current study and GWAS datasets using both fixed ( $P = 9.47 \times 10^{-6}$ ; 1.30 [1.16–1.46]) and random effects ( $P = 0.001$ ; 1.30 [1.11–1.52]) calculations.

**CONCLUSIONS**—We were unable to replicate the confirmed rs4402960/rs1470579 susceptibility variants but found novel evidence for a rare variant in the 3′ downstream region of *IGF2BP2*. Further genetic and functional studies are required to identify the etiological *IGF2BP2* variants. *Diabetes* 57:1992–1996, 2008

The insulin-like growth factor 2 mRNA binding protein 2 (*IGF2BP2*) gene on chromosome 3q27 is a paralog of *IGF2BP1*, a known regulator of *IGF2* gene expression. Genome-wide association studies (GWASs) carried out by the Finland-U.S. Investigation of NIDDM Genetics (FUSION) (1), the Wellcome

Trust Case Control Consortium (WTCCC) (2), and the Diabetes Genetics Initiative (DGI) (3) groups each found modest evidence that single nucleotide polymorphisms (SNPs) in the *IGF2BP2* region are associated with type 2 diabetes. The subsequent meta-analysis of primary and replication datasets from these GWASs corroborated these findings and identified two strongly correlated *IGF2BP2* variants, rs1470579 and rs4402960, as “confirmed” type 2 diabetes susceptibility variants (1–3). By contrast, the French/Canadian GWAS (4) typed 10 SNPs across the *IGF2BP2* locus, including rs1470579, in 1,363 subjects, but found no nominal ( $P < 0.05$ ) association signals at *IGF2BP2*. In an attempt to replicate the *IGF2BP2* association findings in the French Caucasian population in a larger study and to further characterize the susceptibility variants at this novel locus, we performed an association study of HapMap Phase II tag SNPs spanning the *IGF2BP2* locus in 3,093 French Caucasian subjects.

From the <sup>1</sup>Section of Genomic Medicine, Imperial College London, Hammer-smith Campus, London, U.K.; the <sup>2</sup>Endocrinology-Diabetology Unit, Corbeil Hospital, Corbeil, France; the <sup>3</sup>Endocrinology-Diabetology Unit, Bichat Hospital, Paris, France; <sup>4</sup>INSERM U695, Paris, France; the <sup>5</sup>Institut Régional Pour la Santé, Tours, France; <sup>6</sup>INSERM U557/U1125 Inra/Cnam/University Paris, Bobigny, France; <sup>7</sup>INSERM U780-IFR69, Villejuif, France; <sup>8</sup>Paris Univ-Sud, Orsay, France; and <sup>9</sup>CNRS 8090, Institut de Biologie de Lille, Institut Pasteur, Lille, France.

Corresponding author: Fernando Gibson, fernando.gibson@imperial.ac.uk.

Received 17 December 2007 and accepted 17 April 2008.

Published ahead of print at <http://diabetes.diabetesjournals.org> on 22 April 2008. DOI: 10.2337/db07-1789.

© 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**RESEARCH DESIGN AND METHODS**


All subjects were of French Caucasian ancestry. Individuals identified by Sladek et al. (4) as lying outside the HapMap CEU ancestry cluster were excluded from the study. Type 2 diabetic case subjects were known diabetic patients. Normoglycemic control subjects were selected to have a fasting blood glucose concentration  $<7.0$  mmol/l (5). Case subjects were composed of 1) 372 probands from diabetic families (6), recruited in Lille; and 2) 1,083 patients with a family history of type 2 diabetes, recruited at the Corbeil-Essonne Hospital. Control subjects were composed of 1) 353 normoglycemic parents from type 2 diabetic families; 2) 543 subjects from the SUVIMAX (Supplementation en Vitamines et Minéraux Antioxydant) prospective population-based cohort study (7); and 3) 742 subjects selected from the DESIR (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort, a large prospective study of insulin resistance in French subjects (8). Informed consent was obtained from all subjects, and the study was approved by local ethics committees.

## RESEARCH DESIGN AND METHODS

**Statistical power.** The case-control cohort comprised 1,455 type 2 diabetic subjects (age  $60 \pm 12$  years, BMI  $29.0 \pm 6.0$  kg/m<sup>2</sup>, sex [male:female] 56:44%) and 1,638 normoglycemic subjects (aged  $54 \pm 13$  years, BMI  $24.1 \pm 3.3$  kg/m<sup>2</sup>, sex 43:57%). At  $\alpha = 0.05$ , this sample size provided 76% power (9) to detect the type 2 diabetes susceptibility variants rs1470579 and rs4402960, assuming an allele frequency of 0.30, a disease prevalence of 0.1, a heterozygote relative risk of 1.14 (1–3), a multiplicative model, and a 100% genotype call rate.

***IGF2BP2* tag SNP selection.** The genomic target region for tag SNP selection was extended 10 kb upstream and downstream of the NCBI36 *IGF2BP2* locus (chr. 3:186,844,221.0.187,025,521). A total of 19 HapMap Phase II multimarker tagging SNPs (HapMap Data Release 21a/Jan07) with  $r^2$  and minor allele frequency thresholds of 0.8 and 0.05, respectively, were identified for genotyping. In addition, the two GWAS-identified susceptibility variants rs4402960 and rs1470579 (1–3) were added to the genotyped SNP set, making a total of 21 genotyped SNPs.

**SNP genotyping.** Genotyping was performed with the Sequenom MassARRAY iPLEX system (10). SNP genotype frequencies were tested for accordance with Hardy-Weinberg equilibrium using  $\chi^2$  analysis. Regarding quality control, all 21 genotyped SNPs exhibited a call rate  $>90\%$  and a Hardy-Weinberg  $P > 0.05$ , with well-defined genotype clusters. There was no evidence (at  $\alpha = 0.01$ ) of differential call rates across case and control subjects for any SNP (supplementary Table 2 [available in an online appendix at <http://dx.doi.org/10.2337/db07-1789>]).



**Statistical analyses.** To test for association of *IGF2BP2* SNPs with type 2 diabetes,  $\chi^2$  analysis of allele and genotype counts was performed. Pairwise SNP linkage disequilibrium (LD) values were calculated from the genotype data of the control cohort with Haploview (11). Quantitative metabolic phenotypes, BMI, waist-to-hip ratio, fasting serum levels of triacylglycerol, total and HDL cholesterol, glucose, insulin, apolipoprotein A-I (ApoA1), and apolipoprotein B (ApoB), measured in 1,539 normoglycemic subjects from the control cohort, were log transformed and adjusted for age, sex, and BMI, as appropriate. SNPs were tested for association with adjusted quantitative traits using SPSS 14.0 with the ANOVA test under a codominant model. Quantitative trait association  $P$  values are presented uncorrected for multiple testing. Combined analysis of association datasets was carried out with the Mantel-Haenszel (fixed effects) meta-analysis method. Interstudy heterogeneity was assessed with Cochran's  $Q$  statistic and the  $I^2$  metric (12,13). All calculations were performed using R (version 2.5.1) statistical software and the Meta (version 0.8–2) package (14). Association analysis of SNPs captured by multimarker tags was carried out with the PLINK software package (15). Haplotype association was performed with the WHAP (version 2.09) software package (16).

## RESULTS AND DISCUSSION

A total of 21 HapMap Phase II multimarker tag SNPs ( $r^2 \geq 0.8$ ; minor allele frequency  $\geq 0.05$ ) spanning the *IGF2BP2* locus, including the susceptibility variants rs4402960 and rs1470579, were tested for association with type 2 diabetes in 3,093 French subjects. The allele and genotype counts for all SNPs are presented in online supplementary Tables 1 and 2, respectively. Figure 1 shows that SNPs rs4402960 and rs1470579 exhibited very strong LD ( $r^2 = 0.95$ ) in agreement with the GWAS (1–3) and HapMap data (17). However, the allele frequencies of SNPs rs4402960 and rs1470579 were not significantly different in the case and control groups (rs4402960,  $P = 0.632$ ; rs1470579,  $P = 0.896$ ), indicating that these variants were not associated with type 2 diabetes in the present study (Table 1). None of the three SNPs captured by multimarker tags

TABLE 1

Association of *IGF2BP2* SNPs with type 2 diabetes: confirmed susceptibility SNPs rs4402960 and rs1470579 and SNPs showing nominal association ( $P < 0.05$ ) in French Caucasians

SNP	Chr. Position (bp) NCBI36	Gene region*	Allele	Allele count		<i>P</i>	OR (95% CI)
				Type 2 diabetic case subjects (%)	Normoglycemic control subjects (%)		
rs9826022	186,839,954	3' downstream (+4267 bp)	A	2,532 (93.0)	2,949 (95.3)	0.0002	1.53 (1.22–1.91)
			G	190 (7.0)	145 (4.7)		
rs9864104	186,840,225	3' downstream (+3996 bp)	C	2,260 (81.7)	2,628 (84.2)	0.012	1.19 (1.04–1.37)
			T	506 (18.3)	494 (15.8)		
rs4402960	186,994,381	Intron 6	G	1,786 (67.5)	2,111 (68.1)	0.632	1.03 (0.92–1.15)
			T	858 (32.5)	987 (31.9)		
rs1470579	187,011,773	Intron 5	A	1,753 (67.3)	2,120 (67.4)	0.896	1.01 (0.90–1.13)
			C	853 (32.7)	1,024 (32.6)		

Data are *n* (%) unless otherwise indicated. \*Relative to the NCBI36 coordinates of the *IGF2BP2* genomic locus (chr. 3:186,844,221.0.187,025,521).  $\chi^2$  *P* values are shown.

(rs4575929,  $P = 0.159$ ; rs4686692,  $P = 0.566$ ; and rs16860216,  $P = 0.972$ ;) were associated with type 2 diabetes (online supplementary Table 3).

Our inability to replicate the confirmed rs4402960/rs1470579 association result can be attributed to a lack of power to detect this modest signal. An examination of the published association evidence for these variants (Fig. 2A and B and online supplementary Tables 4 and 5) illustrates this point and demonstrates that our results are not inconsistent with those of previous studies. Of the nine published rs4402960 datasets, the three statistically well-powered studies (those with  $\geq 90\%$  power) all obtained an association for this variant, while the six underpowered studies showed either no association or a weak association with type 2 diabetes. Overall, the combined data shows a 3% difference in allele frequency between the case and control groups in over 34,000 subjects, which equates to very strong evidence of association ( $P = 1.9 \times 10^{-14}$ ; OR 1.13 [95% CI 1.10–1.17]). Similarly for the rs1470579 variant, the underpowered datasets were either nonsignificant or weakly associated with type 2 diabetes. The combined data shows a 2% allele frequency difference in over 22,000 case-control subjects and a clearly significant association with type 2 diabetes ( $P = 2.6 \times 10^{-9}$ ; 1.13 [1.09–1.18]). All of this serves as a reminder that the meta-analysis of individually underpowered studies has an invaluable role to play in the identification and confirmation of susceptibility variants of small effect.

The between-study heterogeneity metric  $I^2$  (12,13) was calculated for these two variants (Fig. 2D). Heterogeneity was moderate for rs4402960 ( $I^2 = 21\%$ ) in agreement with a recent study (18). For rs1470579, the meta-analyzed signal is clearly driven by the DGI Replication set “S” result ( $P = 3.73 \times 10^{-8}$ ). In accordance with this standout result and the smaller number of studies available for this SNP, heterogeneity was higher ( $I^2 = 58\%$ ); the random effects OR gave a mere  $P = 0.001$  compared with the Mantel-Haenszel  $P = 2.56 \times 10^{-9}$ ; and Cochran’s *Q* statistic was also statistically significant ( $P = 0.037$ ).

We obtained novel evidence that rs9826022 in the 3' downstream region ( $P = 0.0002$ ; OR 1.53 [95% CI 1.22–1.91]) was associated with type 2 diabetes (Table 1). This result survived Bonferroni correction for the number of SNPs tested (adjusted  $P = 0.003$ ), and we sought confirmation in the publicly available GWAS data. The WTCCC (<http://www.wtccc.org.uk/>) and DGI (<http://www.broad.mit.edu/diabetes/>) GWAS did not directly type the

rs9826022 variant but instead typed rs9878208, an rs9826022 proxy (HapMap  $r^2 = 1$ ). Meta-analysis of this data (Fig. 2C and online supplementary Table 6) provided support for the association, although the random effects evidence ( $P = 0.001$ ) was weaker than that produced by the Mantel-Haenszel analysis ( $P = 9.47 \times 10^{-6}$ ). The heterogeneity between these three studies was moderate ( $I^2 = 44\%$ ). The disparity between the fixed and random effects may indicate that rs9826022 is not the “causative” variant but merely in partial LD with the true susceptibility variant; or it may simply reflect the “winner’s curse” result of the present study and the inherently larger variance of the genetic effect of rare variants in moderately sized studies. The rs9826022 result will clearly require confirmation in further large, independent studies before a definitive assessment of the contribution of this rare variant to type 2 diabetes susceptibility can be made.

The only other nominal association signal, rs9864104 ( $P = 0.012$ ; OR 1.19 [95% CI 1.04–1.37]), was modest and disappeared upon multiple test correction. Since rs9826022 and rs9864104 were in low-moderate LD ( $r^2 = 0.26$ ), we carried out haplotype analysis of these variants. Two SNP haplotypes containing the rare allele of rs9826022 showed a virtually identical frequency and *P* value as the single-point rs9864104 analysis (online supplementary Table 7), indicating that the haplotype analysis did not add anything to the single-point analysis and that the weak rs9864104 signal was caused by this variant being in partial LD with rs9826022. There were no significant differences in SNP allele frequencies between men and women, and no association with type 2 diabetes was uncovered by stratifying for sex (data not shown).

SNPs rs4402960, rs1470579, rs9826022, and rs9864104 were also tested for association with a number of metabolic quantitative phenotypes (online supplementary Table 8). SNPs rs4402960 and rs1470579 presented weak associations with ApoA1 ( $P = 0.019$  and  $0.028$ , respectively). SNP rs9864104 was associated with ApoA1 ( $P = 0.008$ ) and ApoB levels ( $P = 0.002$ ), although there was no linear trend between the three genotype groups. The association of *IGF2BP2* variation with apolipoprotein levels may be consistent with the role of the insulin-like growth factor system in regulating lipid metabolism. However, in the absence of replication, we emphasize that these quantitative trait associations are of nominal significance and require confirmation in further large studies.

In conclusion, we have carried out a comprehensive




FIG. 2. Meta-analysis of the association of *IGF2BP2* SNPs with type 2 diabetes. For each study, the point estimate of the OR with 95% CI is shown. In addition, the summary fixed and random effects are shown for rs4402960 (A), rs1470579 (B), and rs9826022 (C). D: Cochran's Q and  $I^2$  (12,13) statistics for these three variants.

association study of common variation spanning the *IGF2BP2* locus and type 2 diabetes in French Caucasians. We were unable to replicate the confirmed susceptibility variants rs4402960 and rs1470579 but found novel evidence for a rare variant in the 3' downstream region of *IGF2BP2*. Further genetic and functional studies are required to identify the etiological variants at the *IGF2BP2* locus and to determine the cellular and physiological mechanisms by which they act to modulate type 2 diabetes susceptibility.

#### ACKNOWLEDGMENTS

This work was supported by a Wellcome grant to F.G. (WT081510MA).

We thank the anonymous referees and editorial staff for critically appraising and improving draft versions of the manuscript.

#### REFERENCES

- Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M: A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 316:1341-1345, 2007
- Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, Timpson NJ, Perry JR, Rayner NW, Freathy RM, Barrett JC, Shields B,

- Morris AP, Ellard S, Groves CJ, Harries LW, Marchini JL, Owen KR, Knight B, Cardon LR, Walker M, Hitman GA, Morris AD, Doney AS, Burton PR, Clayton DG, Craddock N, Deloukas P, Duncanson A, Kwiatkowski DP, Ouwehand WH, Samani NJ, Todd JA, Donnelly P, Davison D, Easton D, Evans D, Leung HT, Spencer CC, Tobin MD, Attwood AP, Boorman JP, Cant B, Everson U, Hussey JM, Jolley JD, Knight AS, Koch K, Meech E, Nutland S, Prowse CV, Stevens HE, Taylor NC, Walters GR, Walker NM, Watkins NA, Winzer T, Jones RW, McArdle WL, Ring SM, Strachan DP, Pembrey M, Breen G, St Clair D, Caesar S, Gordon-Smith K, Jones L, Fraser C, Green EK, Grozeva D, Hamsheer ML, Holmans PA, Jones IR, Kirov G, Moskvina V, Nikolov I, O'Donovan MC, Owen MJ, Collier DA, Elkin A, Farmer A, Williamson R, McGuffin P, Young AH, Ferrier IN, Ball SG, Balmforth AJ, Barrett JH, Bishop DT, Iles MM, Maqbool A, Yuldasheva N, Hall AS, Braund PS, Dixon RJ, Mangino M, Stevens S, Thompson JR, Bredin F, Tremelling M, Parkes M, Drummond H, Lees CW, Nimmo ER, Satsangi J, Fisher SA, Forbes A, Lewis CM, Onnie CM, Prescott NJ, Sanderson J, Mathew CG, Barbour J, Mohiuddin MK, Todhunter CE, Mansfield JC, Ahmad T, Cummings FR, Jewell DP, Webster J, Brown MJ, Lathrop GM, Connell J, Dominiczak A, Braga Marcano CA, Burke B, Dobson R, Gungadoo J, Lee KL, Munroe PB, Newhouse SJ, Onipinla A, Wallace C, Xue M, Caulfield M, Farrall M, Barton A, Bruce IN, Donovan H, Eyre S, Gilbert PD, Hider SL, Hinks AM, John SL, Potter C, Silman AJ, Symmons DP, Thomson W, Worthington J, Dunger DB, Widmer B, Newport M, Sirugo G, Lyons E, Vannberg F, Hill AV, Bradbury LA, Farrar C, Pointon JJ, Wordsworth P, Brown MA, Franklyn JA, Heward JM, Simmonds MJ, Gough SC, Seal S, Stratton MR, Rahman N, Ban M, Goris A, Sawcer SJ, Compston A, Conway D, Jallow M, Rockett KA, Bumpstead SJ, Chaney A, Downes K, Ghorri MJ, Gwilliam R, Hunt SE, Inouye M, Keniry A, King E, McGinnis R, Potter S, Ravindrarajah R, Whittaker P, Widdon C, Withers D, Cardin NJ, Ferreira T, Pereira-Gale J, Hallgrimsdottir IB, Howie BN, Su Z, Teo YY, Vukcevic D, Bentley D, Compston A, Ouwehand NJ, Samani MR, Isaacs JD, Morgan AW, Wilson GD, Ardern-Jones A, Berg J, Brady A, Bradshaw N, Brewer C, Brice G, Bullman B, Campbell J, Castle B, Cetnarskyj R, Chapman C, Chu C, Coates N, Cole T, Davidson R, Donaldson A, Dorkins H, Douglas F, Eccles D, Eeles R, Elmslie F, Evans DG, Goff S, Goodman S, Goudie D, Gray J, Greenhalgh L, Gregory H, Hodgson SV, Homfray T, Houlston RS, Izatt L, Jackson L, Jeffers L, Johnson-Rofey V, Kavalier F, Kirk C, Lalloo F, Langman C, Locke I, Longmuir M, Mackay J, Magee A, Mansour S, Miedzybrodzka Z, Miller J, Morrison P, Murday V, Paterson J, Pichert G, Porteous M, Rahman N, Rogers M, Rowe S, Shanley S, Sagar A, Scott G, Side L, Snadden L, Steel M, Thomas M, Thomas S, McCarthy MI, Hattersley AT: Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science* 316:1336–1341, 2007
3. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altshuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Bostrom K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Rastam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjogren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumensiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Rieke D, Purcell S: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science* 316:1331–1336, 2007
4. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshezhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P: A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* 445:881–885, 2007
5. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 26 (Suppl. 1):S5–S20, 2003
6. Vionnet N, Hani EH, Dupont S, Gallina S, Francke S, Dotte S, De Matos F, Durand E, Lepretre F, Lecoeur C, Gallina P, Zekiri L, Dina C, Froguel P: Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21–q24. *Am J Hum Genet* 67:1470–1480, 2000
7. Hercberg S, Preziosi P, Briancon S, Galan P, Triol I, Malvy D, Roussel AM, Favier A: A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study—design, methods, and participant characteristics: Supplementation en Vitamines et Mineraux Antioxydants. *Control Clin Trials* 19:336–351, 1998
8. Balkau B: [An epidemiologic survey from a network of French Health Examination Centres, (D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome]. *Rev Epidemiol Sante Publique* 44:373–375, 1996 [in French]
9. Purcell S, Cherny SS, Sham PC: Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* 19:149–150, 2003
10. Jurinck C, van den Boom D, Cantor CR, Koster H: Automated genotyping using the DNA MassArray technology. *Methods Mol Biol* 187:179–192, 2002
11. Barrett JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 21:263–265, 2005
12. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. *Stat Med* 21:1539–1558, 2002
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. *BMJ* 327:557–560, 2003
14. Team RDC: *R: A Language and Environment for Statistical Computing*. Vienna, Austria, R Foundation for Statistical Computing, 2007
15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC: PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81:559–575, 2007
16. Purcell S, Daly MJ, Sham PC: WHAP: haplotype-based association analysis. *Bioinformatics* 23:255–256, 2007
17. Frazer KA, Ballinger DG, Cox DR, Hinds DA, Stuve LL, Gibbs RA, Belmont JW, Boudreau A, Hardenbol P, Leal SM, Pasternak S, Wheeler DA, Willis TD, Yu F, Yang H, Zeng C, Gao Y, Hu H, Hu W, Li C, Lin W, Liu S, Pan H, Tang X, Wang J, Wang Y, Yu J, Zhang B, Zhang Q, Zhao H, Zhao H, Zhou J, Gabriel SB, Barry R, Blumenstiel B, Camargo A, Defelice M, Faggart M, Goyette M, Gupta S, Moore J, Nguyen H, Onofrio RC, Parkin M, Roy J, Stahl E, Winchester E, Ziaugra L, Altshuler D, Shen Y, Yao Z, Huang W, Chu X, He Y, Jin L, Liu Y, Shen Y, Sun W, Wang H, Wang Y, Wang Y, Xiong X, Xu L, Waye MM, Tsui SK, Xue H, Wong JT, Galver LM, Fan JB, Gunderson K, Murray SS, Oliphant AR, Chee MS, Montpetit A, Chagnon F, Ferretti V, Leboeuf M, Olivier JF, Phillips MS, Roumy S, Sallee C, Verner A, Hudson TJ, Kwok PY, Cai D, Koboldt DC, Miller RD, Pawlikowska L, Taillon-Miller P, Xiao M, Tsui LC, Mak W, Song YQ, Tam PK, Nakamura Y, Kawaguchi T, Kitamoto T, Morizono T, Nagashima A, Ohnishi Y, Sekine A, Tanaka T, Tsunoda T, Deloukas P, Bird CP, Delgado M, Dermitzakis ET, Gwilliam R, Hunt S, Morrison J, Powell D, Stranger BE, Whittaker P, Bentley DR, Daly MJ, de Bakker PI, Barrett J, Chretien YR, Maller J, McCarroll S, Patterson N, Pe'er I, Price A, Purcell S, Richter DJ, Sabeti P, Saxena R, Schaffner SF, Sham PC, Varilly P, Altshuler D, Stein LD, Krishnan L, Smith AV, Tello-Ruiz MK, Thorisson GA, Chakravarti A, Chen PE, Cutler DJ, Kashuk CS, Lin S, Abecasis GR, Guan W, Li Y, Munro HM, Qin ZS, Thomas DJ, McVean G, Auton A, Bottolo L, Cardin N, Eyheramendy S, Freeman C, Marchini J, Myers S, Spencer C, Stephens M, Donnelly P, Cardon LR, Clarke G, Evans DM, Morris AP, Weir BS, Tsunoda T, Mullikin JC, Sherry ST, Feolo M, Skol A, Zhang H, Zeng C, Zhao H, Matsuda I, Fukushima Y, Macer DR, Suda E, Rotimi CN, Adebamowo CA, Ajayi I, Aniagwu T, Marshall PA, Nkwodim-mah C, Royal CD, Leppert MF, Dixon M, Peiffer A, Qiu R, Kent A, Kato K, Niikawa N, Adewole IF, Knoppers BM, Foster MW, Clayton EW, Watkin J, Gibbs RA, Belmont JW, Muzny D, Nazareth L, Sodergren E, Weinstock GM, Wheeler DA, Yakub I, Gabriel SB, Onofrio RC, Richter DJ, Ziaugra L, Birren BW, Daly MJ, Altshuler D, Wilson RK, Fulton LL, Rogers J, Burton J, Carter NP, Clee CM, Griffiths M, Jones MC, McLay K, Plumb RW, Ross MT, Sims SK, Willey DL, Chen Z, Han H, Kang L, Godbout M, Wallenburg JC, L'Archeveque P, Bellemare G, Saeki K, Wang H, An D, Fu H, Li Q, Wang Z, Wang R, Holden AL, Brooks LD, McEwen JE, Guyer MS, Wang VO, Peterson JL, Shi M, Spiegel J, Sung LM, Zacharia LF, Collins FS, Kennedy K, Jamieson R, Stewart J: A second generation human haplotype map of over 3.1 million SNPs. *Nature* 449:851–861, 2007
18. Ioannidis JP, Patsopoulos NA, Evangelou E: Heterogeneity in meta-analyses of genome-wide association investigations. *PLoS ONE* 2:e841